{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:34:15Z","timestamp":1753893255086,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Programmed cell death 1 (PD-1) inhibitor has been in the market in China for several years, which lacks sufficient domestic evidence regarding its application in lung cancer. Thus, this study intended to assess the treatment outcome and tolerance of PD-1 inhibitor plus chemotherapy in advanced, driver-gene-negative, nonsquamous, non-small-cell lung cancer (NSCLC) patients in a real clinical setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study analyzed 68 advanced driver-gene-negative nonsquamous NSCLC patients, among which 38 cases received PD-1 inhibitor plus chemotherapy and 30 cases adopted chemotherapy alone. Disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Generally, PD-1 inhibitor plus chemotherapy achieved a more satisfying ORR compared with chemotherapy alone (52.6% vs. 30.0%, <jats:italic>P\u2009<\/jats:italic>=\u20090.061), while the DCR did not vary between PD-1 inhibitor plus chemotherapy and chemotherapy (84.2% vs. 73.3%, <jats:italic>P\u2009<\/jats:italic>=\u20090.271). Patients receiving PD-1 inhibitor plus chemotherapy exhibited favorable PFS (median: 10.1 vs. 7.1 months, <jats:italic>P\u2009<\/jats:italic>=\u20090.040) and OS (median: 17.4 vs. 13.9 months, <jats:italic>P\u2009<\/jats:italic>=\u20090.049) than patients adopting chemotherapy alone. Additionally, after adjustment using multivariable Cox's analyses, PD-1 inhibitor plus chemotherapy (vs. chemotherapy) could independently realize prolonged PFS (<jats:italic>P\u2009<\/jats:italic>=\u20090.020) and OS (<jats:italic>P\u2009<\/jats:italic>=\u20090.029). Moreover, the majority of adverse events were manageable; meanwhile, grade 3\u20134 adverse events included leukopenia (13.2%), neutropenia (13.2%), nausea and vomiting (7.9%), anemia (5.3%), elevated transaminase (5.3%), thrombopenia (2.6%), anorexia (2.6%), peripheral neuropathy (2.6%), and rash (2.6%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PD-1 inhibitor plus chemotherapy exhibits a better efficacy and equal tolerance compared with chemotherapy alone in advanced driver-gene-negative nonsquamous NSCLC patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2022.954490","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T06:11:59Z","timestamp":1662012719000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study"],"prefix":"10.3389","volume":"9","author":[{"given":"Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-20-3136","article-title":"Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy","volume":"27","author":"Zhou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11864-019-0675-9","article-title":"Diagnosis and treatment of ALK aberrations in metastatic NSCLC","volume":"20","author":"Friedlaender","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.3390\/ijms20225701","article-title":"Current approaches in NSCLC targeting K-RAS and EGFR","volume":"20","author":"Aran","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","volume":"38","author":"Hanna","year":"2020","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"B10","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/s41416-022-01743-4","article-title":"Biomarkers of response to PD-1 pathway blockade","volume":"126","author":"Li","year":"2022","journal-title":"Br J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"773168","DOI":"10.3389\/fimmu.2021.773168","article-title":"What happens to the immune microenvironment after PD-1 inhibitor therapy?","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.954490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T06:12:01Z","timestamp":1662012721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.954490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":18,"alternative-id":["10.3389\/fsurg.2022.954490"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.954490","relation":{},"ISSN":["2296-875X"],"issn-type":[{"type":"electronic","value":"2296-875X"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"article-number":"954490"}}